Skip to main content
SpringerLink
Log in

Targeting an Early and Substantial Increase in Mean Arterial Pressure Is Critical in the Management of Type 1 Hepatorenal Syndrome: A Combined Retrospective and Pilot Study

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Appreciation of the central role for arterial vasodilatation in the pathogenesis of hepatorenal syndrome (HRS) has led to routine use of vasoconstrictors in combination with albumin as a medical therapy for HRS. Various vasoconstrictors have been explored but the optimal approach for such therapies has not yet been established.

Aims

The purpose of this study was to examine the role of targeting an early and substantial increase in mean arterial pressure (MAP) in the management of type 1 HRS, a condition associated with very poor prognosis.

Methods

A total of 59 patients with type 1 HRS who received a combination therapy of vasoconstrictors and albumin were enrolled into a retrospective cohort study. Subjects having a substantial increase of more than 10 mmHg in MAP by day 3 after initiation of therapy were categorized as MAP responders and the rest as MAP non-responders. In addition, five patients were enrolled into a prospective pilot study in which a titration protocol of vasoconstrictors was followed to achieve early goal-directed therapy (EGDT).

Results

MAP responders achieved significantly higher incidence of treatment success or total response, less requirement of dialysis and more incidence of liver transplantation. More importantly, this response is associated with better short-term and long-term overall survival as well as transplant-free survival. The effectiveness of such an approach was further confirmed in the pilot study which followed an EGDT protocol.

Conclusions

Using an early and substantial increase in MAP as a therapeutic target is associated with favorable clinical outcomes in the management of type 1 HRS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236.

    CAS  PubMed  Google Scholar 

  2. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet. 2003;362:1819–1827.

    Article  CAS  PubMed  Google Scholar 

  3. Chok KS, Fung JY, Chan SC, et al. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl. 2012;18:779–785.

    Article  PubMed  Google Scholar 

  4. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004;40:140–146.

    Article  PubMed  Google Scholar 

  5. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–447.

    Article  CAS  PubMed  Google Scholar 

  6. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690–1697.

    Article  CAS  PubMed  Google Scholar 

  7. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and tips in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55–64.

    Article  CAS  PubMed  Google Scholar 

  8. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360–1368.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941–948.

    CAS  PubMed  Google Scholar 

  10. Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352–1359.

    Article  CAS  PubMed  Google Scholar 

  11. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type i hepatorenal syndrome: a pilot study. Hepatology. 2002;36:374–380.

    Article  CAS  PubMed  Google Scholar 

  12. Giostra E, Ruedin P, Cunningham M, et al. Sustained effects of ornipressin in hepatorenal syndrome. J Hepatol. 1995;22:120–121.

    Article  CAS  PubMed  Google Scholar 

  13. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47:499–505.

    Article  CAS  PubMed  Google Scholar 

  14. Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56:1293–1298.

    Article  CAS  PubMed  Google Scholar 

  15. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transpl. 2005;20:1813–1820.

    Article  CAS  Google Scholar 

  16. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51:219–226.

    Article  CAS  PubMed  Google Scholar 

  17. Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis. 2011;58:928–938.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (hrs) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315–321.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–1318.

    CAS  PubMed  Google Scholar 

  20. Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med. 2009;35:152–156.

    Article  CAS  PubMed  Google Scholar 

  21. Malbrain ML, Cheatham ML, Kirkpatrick A, et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. I. Definitions. Intensive Care Med. 2006;32:1722–1732.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Geetha Maddukuri was supported by an educational fund from the US Department of Veteran Affairs. We are grateful to the Saint Louis University hepatology team including Drs. Alex Befeler, Brent Neuschwander-Tetri, Lliana Bouneva, Adrian Di Bisceglie, and Bruce Bacon for their support during the study period.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, St. Louis University, St. Louis, MO, 63110, USA

    Geetha Maddukuri, Farnaz Mohammadi & Zhiwei Zhang

  2. Division of Gastroenterology and Hepatology, Department of Medicine, St. Louis University, St. Louis, MO, 63110, USA

    Cindy X. Cai & Satish Munigala

  3. Division of Gastroenterology, Department of Medicine, VA Loma Linda Healthcare System, Loma Linda University, Loma Linda, CA, 92357, USA

    Cindy X. Cai

  4. Division of Nephrology, Department of Medicine, VA Loma Linda Healthcare System (111N), Loma Linda University, 11201 Benton Street, Loma Linda, CA, 92357, USA

    Zhiwei Zhang

Authors
  1. Geetha Maddukuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cindy X. Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satish Munigala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Farnaz Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiwei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhiwei Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maddukuri, G., Cai, C.X., Munigala, S. et al. Targeting an Early and Substantial Increase in Mean Arterial Pressure Is Critical in the Management of Type 1 Hepatorenal Syndrome: A Combined Retrospective and Pilot Study. Dig Dis Sci 59, 471–481 (2014). https://doi.org/10.1007/s10620-013-2899-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-013-2899-z

Keywords

Search

Navigation